What the FDA labels say about taking them together
Apomorphine and ondansetron
Apomorphine's FDA label of February 24, 2022 names ondansetron in its contraindications section, and ondansetron's label names apomorphine too. The apomorphine label: “CONTRAINDICATIONS ONAPGO is contraindicated in patients: Using concomitant 5HT 3 antagonists, including antiemetics and alosetron.”
Check it at the source: the apomorphine FDA label on DailyMed (effective February 24, 2022, TruPharma, LLC); the ondansetron FDA label on DailyMed (effective January 8, 2026, Glenmark Pharmaceuticals Inc., USA).
What does the apomorphine label say about ondansetron?
Apomorphine label, contraindicationsCONTRAINDICATIONS Apomorphine hydrocloride is contraindicated in patients: Using concomitant drugs of the 5HT 3 antagonist class including antiemetics (e.g., ondansetron, granisetron, dolasetron, palonosetron) and alosetron [see Drug Interactions (7.1) ].
Apomorphine label, drug interactionsDRUG INTERACTIONS Concomitant use of antihypertensive medications and vasodilators: increased risk for hypotension, myocardial infarction, pneumonia, falls, and injuries ( 7.2 ) Dopamine antagonists such as neuroleptics or metoclopramide, may diminish the effectiveness of apomorphine hydrocloride ( 7.4 ) 7.1 5HT 3 Antagonists Based on reports of profound hypotension and loss of consciousness when apomorphine hydrocloride was administered with ondansetron, the concomitant use of apomorphine hydrocloride with 5HT 3 antagonists including antiemetics (for example, ondansetron, granisetron, dolasetron, palonosetron) and alosetron, is contraindicated.
Source: FDA drug label (Onapgo, NDA214056), MDD US Operations, LLC, a subsidiary of Supernus Pharmaceuticals, Inc, effective July 10, 2026 (SPL set f3552b6e-5ae7-4993-aa1a-e399c4a7080a), via openFDA
Source: FDA drug label (apomorphine hydrocloride), ANDA212025 (Tp Anda Holdings), as published by TruPharma, LLC, effective February 24, 2022 (SPL set aedf70e4-1949-44bc-bf1b-0f282c4f0705), via openFDA; the full label on DailyMed
What does the ondansetron label say about apomorphine?
Ondansetron label, contraindicationsreceiving concomitant apomorphine due to the risk of profound hypotension and loss of consciousness Patients known to have hypersensitivity (e.g., anaphylaxis) to ondansetron or any components of the formulation.
Source: FDA drug label (Ondansetron), Glenmark Pharmaceuticals Inc., USA, effective January 8, 2026 (SPL set eee5217a-eba8-463a-812d-bf3c66f0934f), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Apomorphine | Ondansetron | |
|---|---|---|
| Labeled for | Parkinson's disease | Nausea and vomiting |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | n/a | $0.0582 per tablet 4 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once